FCA
JBIO

FinTrust Capital Advisors’s Jade Biosciences JBIO Stock Holding History

FinTrust Capital Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$1K – 1220
2022
Q2 		$1K Buy
+2
New +$955 ﹤0.01% 1156

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FinTrust Capital Advisors's JBIO Position: Q3 2022 in Review

FinTrust Capital Advisors sold out of Jade Biosciences (JBIO) in Q3 2022, closing a stake of 2 shares — an estimated $1K sold.

FinTrust Capital Advisors first reported a position in JBIO in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 55 funds tracked by Wall St. Rank hold JBIO as of Q3 2022.

  • FinTrust Capital Advisors reported no remaining Jade Biosciences position as of Q3 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 2 Jade Biosciences shares in Q3 2022, an estimated $1K.
  • FinTrust Capital Advisors first reported a position in Jade Biosciences in Q2 2022 and held it in 1 quarter.
  • FinTrust Capital Advisors's Jade Biosciences position peaked at $1K in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2022.

Based on FinTrust Capital Advisors's 13F filing for Q3 2022, filed 20 Oct 2022.